8.07010.40% ( +0.760 )
Closed: Nov 3, 16:00:01 (EDT)Current ValuationThe current P/E ratio is -5.32, above the reasonable range, cheaper than 3.12% of the time in the past 1 years, and the industry ranks 391/606, the industry Median -1.90.
-5.32xP/E
$8.07Stock price
$-1.52Earnings per share
-5.32xP/E
Stock price$8.07Earnings per share$-1.52
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -5.97x
- Typical range
- -7.46x–-5.68x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
013263952
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
GILDUSGilead Sciences | -53.77x | 161.61% | $207.66B |
MRNAUSModerna | -28.94x | 16.99% | $91.20B |
CSLLYUSCSL Limited | -25.73x | -- | $66.36B |
NTRAUSNatera | -291.24x | 5.57% | $56.02B |
RVMDUSRevolution Medicines | -23.54x | 61.94% | $41.63B |
ROIVUSRoivant Sciences | -97.77x | 146.69% | $26.03B |
INSMUSInsmed | -37.66x | 75.15% | $22.81B |
BNTXUSBioNTech SE | -12.90x | 22.98% | $21.83B |
BBIOUSBridgebio Pharma | -24.44x | 31.08% | $14.47B |
SMMTUSSummit Therapeutics | -14.72x | 20.06% | $12.60B |
BMRNUSBioMarin Pharma | -563.66x | 57.02% | $10.77B |
KYMRUSKymera Therapeutics | -30.24x | 8.45% | $10.57B |
PCVXUSVaxcyte | -8.99x | 47.91% | $9.57B |
TWSTUSTwist Bioscience | -67.56x | 28.63% | $9.24B |
MDGLUSMadrigal Pharma | -58.90x | 50.98% | $9.16B |
IBRXUSImmunityBio | -8.85x | 151.32% | $8.79B |
SYREUSSpyre Therapeutics | -58.27x | 45.60% | $8.75B |
CYTKUSCytokinetics | -9.69x | 7.04% | $8.66B |
ARWRUSArrowHead Pharma | -26.28x | 35,923.70% | $8.41B |
PRAXUSPraxis Precision Medicines | -23.09x | 3.71% | $7.83B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
